The European Commission (EC) has authorised a variation of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) to treat patients with mild, moderate or severe renal impairment.
VBI Vaccines has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for VBI-1901 to treat glioblastoma (GBM), a most common primary brain cancer.
AbbVie has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for atogepant (Qulipta) to support the label expansion to treat chronic migraine in adults.
The US Food and Drug Administration (FDA) has approved AbbVie’s approved Skyrizi (risankizumab-rzaa) for the treatment of Crohn's disease (CD) in adults.
Eli Lilly and Incyte have received the US Food and Drug Administration (FDA) approval for Olumiant (baricitinib) to treat adult patients with severe alopecia areata (AA).
Roche has received conditional marketing authorisation from the European Commission (EC) for Lunsumio (mosunetuzumab) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).
The US Food and Drug Administration (FDA) has granted approval for Sanofi and Regeneron’s Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in children aged six months to five years.
The US Food and Drug Administration (FDA) has approved the use of GSK’s Priorix to prevent measles, mumps and rubella (MMR) in children aged 12 months and older.
China’s National Medical Products Administration (NMPA) has approved CStone Pharmaceuticals’ sugemalimab (Cejemly) for unresectable stage III non-small cell lung cancer (NSCLC) treatment.
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to VBI Vaccines’ PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)].
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.